Evolution of multiple sclerosis in France since the beginning of hepatitis B vaccination

被引:18
|
作者
Le Houezec, Dominique [1 ]
机构
[1] REVAHB Reseau Vaccin Hepatite B French, F-14000 Caen, France
关键词
Hepatitis B vaccine; Multiple sclerosis; Demyelinating disease; Pharmacovigilance; Vaccine adverse events; AUTOIMMUNITY;
D O I
10.1007/s12026-014-8574-4
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Since the implementation of the mass vaccination campaign against hepatitis B in France, the appearance of multiple sclerosis, sometimes occurring in the aftermath of vaccinations, led to the publication of epidemiological international studies. This was also justified by the sharp increase in the annual incidence of multiple sclerosis reported to the French health insurance in the mid-1990s. Almost 20 years later, a retrospective reflection can be sketched from these official data and also from the national pharmacovigilance agency. Statistical data from these latter sources seem to show a significant correlation between the number of hepatitis B vaccinations performed and the declaration to the pharmacovigilance of multiple sclerosis occurring between 1 and 2 years later. The application of the Hill's criteria to these data indicates that the correlation between hepatitis B vaccine and multiple sclerosis may be causal.
引用
收藏
页码:219 / 225
页数:7
相关论文
共 50 条